Plant-Based Vaccines Market Size and Forecast — 2026-2033
Plant-Based Vaccines Market is estimated to be valued at USD 332.8 Mn in 2026 and is expected to reach USD 6,097.2 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 51.5% from 2026 to 2033.
Analysts’ Views on the Global Plant-based Vaccines Market:
The increasing research and development of plant-based vaccines is expected to drive the growth of the market over the forecast period. For instance, according to data published in September 2021 by Genetic Engineering & Biotechnology News University of California-Riverside, researchers are studying whether it can turn edible plants like lettuce into mRNA vaccine factories.
Figure 1. Global Plant-based Vaccines Market Share (%), By Application, 2026

Global Plant-based Vaccines Market - Drivers
- Increasing research and development activities: Increasing research and development activities are expected to drive the growth of the global plant-based vaccines market over the forecast period. The study is currently in phase 2. The study is estimated to be completed in April 2026.
Figure 2. Global Plant-based Vaccines Market Share (%), By Region, 2026

Global Plant-based Vaccines Market - Regional Analysis
Among regions, North America is estimated to hold a dominant position in the global plant-based vaccines market over the forecast period. The global plant-based vaccines market is expected to witness significant growth in the coming years, driven by the increasing technology advancement of plant based vaccines.
- Current Industry Events of 2026
- Market Size Estimation
- Regional Breakdown
- Competitive Landscape
- Customer Intelligence
- Segmental Analysis
- Pricing Analysis
- Key Market Drivers, Challenges & Future Trends
- Customized Insights Section
Plant-based Vaccines Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 332.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 51.5% | 2033 Value Projection: | USD 6,097.2 Mn |
| Geographies covered: |
| ||
| Segments covered: |
| ||
| Companies covered: | Medicago, Inc., IBIO, Inc., Icon Genetics GmbH, Lumen Bioscience, Inc., British American Tobacco Plc., Creative Biolabs, Inc., Leaf Expression Systems Ltd., ZYUS Life Sciences Inc., PlantForm Corporation, and Infectious Disease Research Institute (IDRI). | ||
| Growth Drivers: |
| ||
| Restraints & Challenges: |
| ||
- In many countries, hospitals and ICU departments are overloaded or on the verge of a potential collapse. Therefore, optimal allocation of healthcare resources is required. Healthcare professionals are forced to treat severely ill patients with limited access to ventilation equipment, qualified intensive care personnel, or protective patient monitoring devices.
Global Plant-based Vaccines Market Segmentation:
The global plant-based vaccines market report is segmented into vaccine type, source, application and region.
- By vaccine type, the market is segmented into bacterial vaccines, viral vaccines, parasite vaccines and others. Out of which, the bacterial vaccine segment is expected to hold a dominant position in the global plant-based vaccines market during the forecast period. Bacterial vaccines contain killed or attenuated bacteria that activate the immune system. Antibodies are built against that particular bacteria, and prevents bacterial infection later.
- By application,ebolavirus, poultry disease, and others. For instance, in February 2022, Medicago AB, a biopharmaceutical company, announced that Health Canada had granted approval for the COVIFENZ,, (plant-based virus-like particles [VLP], recombinant, adjuvanted).
- By source, the market is segmented into tobacco plant, maize, potato, and others. Out of which, tobacco plant is expected to dominate the market over the forecast period, and this is attributed to the increasing launch of new companies. For instance, in January 2022, British American Tobacco (BAT), a multi-category consumer goods company that provides tobacco and nicotine products, launched Kentucky BioProcessing (KBP), a wholly owned subsidiary of British American Tobacco (BAT). The new company will focus on using tobacco plants to develop biologics and vaccines for rare and infectious diseases.
Global Plant-based Vaccines Market - Cross Sectional Analysis:
Increasing prevalence of the Ebola Virus in Africa is expected to drive the growth of the Africa market over the forecast period. For instance, according to data published in December 2021 by the National Library of Medicine, in 2020, 3470 Ebola virus disease cases had been reported, including 3317 confirmed and 153 probable cases, with 2287 deaths in the Democratic Republic of the Congo, Africa.
Global Plant-based Vaccines Market: Key Developments
- On September 24, 2020, Lumen Bioscience, Inc.,a pharmaceutical company, received US$ 4 million grant from Series B financing round from the investors such as WestRiver Management, Bioeconomy Capital, and others.
- In June 2022, Mazen Animal Health, a biotechnology company, announced that the company is getting closer to completing the development of a novel vaccine that would be produced in corn and administered through animal feed.
Global Plant-based Vaccines Market: Key Trends
- Increasing funding by the government: Increasing funding by the government for the development of plant-based vaccines is expected to drive the growth of the global plant-based vaccines market over the forecast period. For instance, according to data published in May 2022 by HT Digital Streams Ltd, an online news company, the Canadian government provided US$173 million in funding to Medicago Inc., a biotechnology company, for its development of Covifenz, the world’s first plant-based COVID vaccine.
Global Plant-based Vaccines Market: Restraint
- Disadvantages and potential risk of contamination and environmental risks: Disadvantages and potential risks of contamination and environmental risks are expected to hinder the growth of the global plant-based vaccines market in the near future. Pollen contamination difficulties with field crop-based Plant Molecular Farming (PMF) platforms, such as platforms based on maize or rice, create biosafety concerns as pollen may contaminate non-transgenic crops that are part of standard agricultural production. Currently, the U.S. FDA has a restricted policy for using food crops for the production of recombinant pharmaceutical compounds.
Global Plant-based Vaccines Market - Key Players
The major players operating in the global plant-based vaccines market include Medicago, Inc., IBIO, Inc., Icon Genetics GmbH, Lumen Bioscience, Inc., British American Tobacco Plc., Creative Biolabs, Inc., Leaf Expression Systems Ltd., ZYUS Life Sciences Inc., PlantForm Corporation, and Infectious Disease Research Institute (IDRI).
Sources
Primary Research Interviews
- Plant-based vaccine developers (Medicago [legacy], iBio, Kentucky BioProcessing)
- Molecular farming and plant biotech researchers
- Regulatory scientists working on recombinant plant-derived biologics
Databases
- ClinicalTrials.gov
- WHO Vaccine Pipeline Tracker
Magazines
- GEN
- BioProcess International
Journals
- Vaccine (Elsevier)
- Plant Biotechnology Journal
- Nature Plants
Newspapers
- Reuters Health
Associations
- International Society for Plant Molecular Farming (ISPMF)
Public Domain Sources
- U.S. FDA – Biologics
- European Medicines Agency (EMA)
Proprietary Elements
- CMI Data Analytics Tool, Proprietary CMI Existing Repository of information for last 10 years.
Definition: Plant-derived vaccines are produced by recombinant technology, in which the gene encoding the desired antigen protein is integrated into the plant genome. Agrobacterium tumefaciens is commonly used for gene transfer and transformation.
Get access to 250+ pages report
Every segment, forecast, competitor profile and data table behind the analysis above — available for instant download.
- ESOMAR Member
- ISO 9001:2015 Certified
- D-U-N-S Registered
- GDPR & CCPA Compliant
Missing comfort of reading report in your local language? Find your preferred language:
Transform your Strategy with Exclusive Trending Reports
Frequently Asked Questions
The Plant-Based Vaccines Market is estimated to be valued at USD 332.8 Mn in 2026, and is expected to reach USD 6,097.2 Mn by 2033.
The CAGR of the Plant-Based Vaccines Market is projected to be 51.5% from 2026 to 2033.
Increasing prevalence of COVID-19 and increasing research and development activities are expected to drive the market growth.
Covid-19 is the leading application segment in the market.
Disadvantages and potential risks of contamination and environmental risks are expected to hinder the market over the forecast period.
The major players operating in the market are Medicago, Inc., IBIO, Inc., Icon Genetics GmbH, Lumen Bioscience, Inc., British American Tobacco Plc., Creative Biolabs, Inc., Leaf Expression Systems Ltd., ZYUS Life Sciences Inc., PlantForm Corporation, and Infectious Disease Research Institute (IDRI).
